MALVERN, PA--(MARKET WIRE)--Sep 10, 2007 -- Auxilium Pharmaceuticals, Inc. (NasdaqGM:AUXL - News) today announced that the first patients have been dosed in the Company’s second U.S. phase III pivotal trial and the Australian phase III study for XIAFLEX(TM) for the treatment of Dupuytren’s contracture, a disabling and recurring condition in which the joints in the hand contract, impairing patients’ ability to straighten and move their fingers.
